πŸ‡ΊπŸ‡Έ FDA
Patent

US 12065448

Heteroaryl plasma kallikrein inhibitors

granted A61PA61P29/02

Quick answer

US patent 12065448 (Heteroaryl plasma kallikrein inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P29/02